- Home
- UPB vs KLTO Comparison
UPB vs KLTO Comparison
Compare UPB & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- KLTO
- Stock Information
- Founded
- UPB 2021
- KLTO 2019
- Country
- UPB United States
- KLTO United States
- Employees
- UPB N/A
- KLTO N/A
- Industry
- UPB
- KLTO
- Sector
- UPB
- KLTO
- Exchange
- UPB NYSE
- KLTO NYSE
- Market Cap
- UPB 521.3M
- KLTO 5.9M
- IPO Year
- UPB 2024
- KLTO N/A
- Fundamental
- Price
- UPB $11.13
- KLTO $1.19
- Analyst Decision
- UPB Strong Buy
- KLTO
- Analyst Count
- UPB 4
- KLTO 0
- Target Price
- UPB $56.50
- KLTO N/A
- AVG Volume (30 Days)
- UPB 500.3K
- KLTO 91.8M
- Earning Date
- UPB 08-14-2025
- KLTO 08-15-2025
- Dividend Yield
- UPB N/A
- KLTO N/A
- EPS Growth
- UPB N/A
- KLTO N/A
- EPS
- UPB N/A
- KLTO N/A
- Revenue
- UPB $2,296,000.00
- KLTO N/A
- Revenue This Year
- UPB N/A
- KLTO N/A
- Revenue Next Year
- UPB N/A
- KLTO N/A
- P/E Ratio
- UPB N/A
- KLTO N/A
- Revenue Growth
- UPB N/A
- KLTO N/A
- 52 Week Low
- UPB $5.14
- KLTO $0.11
- 52 Week High
- UPB $29.46
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- KLTO N/A
- Support Level
- UPB N/A
- KLTO N/A
- Resistance Level
- UPB N/A
- KLTO N/A
- Average True Range (ATR)
- UPB 0.00
- KLTO 0.00
- MACD
- UPB 0.00
- KLTO 0.00
- Stochastic Oscillator
- UPB 0.00
- KLTO 0.00
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.